Prostate cancer screening in Europe: future directions and perspectives

Affiliations

¹ Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. m.j.vanharten-4@umcutrecht.nl.
² Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Review

M J van Harten et al. Prostate Cancer Prostatic Dis. 2026 Mar.

. 2026 Mar;29(1):100-102.

doi: 10.1038/s41391-025-00989-2. Epub 2025 Jun 10.

¹ Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands. m.j.vanharten-4@umcutrecht.nl.
² Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

No abstract available

Conflict of interest statement

Competing interests: The authors declare no competing interests.

1. Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76:43–51. - DOI - PubMed - PMC
1. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65:1046–55. - DOI - PubMed - PMC
1. Patasius A, Krilaviciute A, Smailyte G. Prostate cancer screening with psa: Ten years’ experience of population based early prostate cancer detection programme in lithuania. J Clin Med. 2020;9:3826. - DOI - PubMed - PMC
1. Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol. 2022;19:562–72. - DOI - PubMed
1. Wallström J, Geterud K, Kohestani K, Maier SE, Månsson M, Pihl CG, et al. Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial. Eur Radio. 2021;31:8692–702. - DOI